GeneFerm Biotechnology Valuation
Is 1796 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1796 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1796 (NT$57.5) is trading above our estimate of fair value (NT$29.6)
Significantly Below Fair Value: 1796 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1796?
Other financial metrics that can be useful for relative valuation.
| What is 1796's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | NT$2.38b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3x |
| Enterprise Value/EBITDA | 10.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 1796's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.6x | ||
4109 Jia Jie Biomedical | 17x | n/a | NT$2.4b |
1731 Maywufa | 19.2x | n/a | NT$3.2b |
6242 Li Kang Biomedical | 14.7x | n/a | NT$1.6b |
1783 Maxigen Biotech | 23.6x | n/a | NT$3.9b |
1796 GeneFerm Biotechnology | 19.1x | n/a | NT$2.4b |
Price-To-Earnings vs Peers: 1796 is expensive based on its Price-To-Earnings Ratio (19.1x) compared to the peer average (18.6x).
Price to Earnings Ratio vs Industry
How does 1796's PE Ratio compare vs other companies in the Asian Personal Products Industry?
Price-To-Earnings vs Industry: 1796 is good value based on its Price-To-Earnings Ratio (19.1x) compared to the Asian Personal Products industry average (24x).
Price to Earnings Ratio vs Fair Ratio
What is 1796's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 19.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1796's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.